Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher
Crossmark

Economic Burden Evaluation of Cutaneous Leishmaniasis in Iran

Mojtaba Salimi 1 , Abedin Saghafipour ORCID 2 , * , Hadi Hamidi Parsa 3 , Majid Khosravi 3 and Mohammad Reza Shirzadi 4
Authors Information
1 Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Public Health, Faculty of Health, Qom University of Medical Sciences, Qom, Iran
3 Qom University of Medical sciences, Qom, Iran
4 Communicable Diseases Management Center, Ministry of Health and Medical Education, Tehran, Iran
Article information
  • Shiraz E-Medical Journal: 20 (6); e82810
  • Published Online: May 7, 2019
  • Article Type: Research Article
  • Received: August 1, 2018
  • Revised: November 24, 2018
  • Accepted: December 1, 2018
  • DOI: 10.5812/semj.82810

To Cite: Salimi M, Saghafipour A, Hamidi Parsa H , Khosravi M , Shirzadi M R . Economic Burden Evaluation of Cutaneous Leishmaniasis in Iran, Shiraz E-Med J. Online ahead of Print ; 20(6):e82810. doi: 10.5812/semj.82810.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: Review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis. 2012;6(2). e1475. doi: 10.1371/journal.pntd.0001475. [PubMed: 22389729]. [PubMed Central: PMC3289601].
  • 2. Akhoundi M, Kuhls K, Cannet A, Votypka J, Marty P, Delaunay P, et al. A historical overview of the classification, evolution, and dispersion of leishmania parasites and sandflies. PLoS Negl Trop Dis. 2016;10(3). e0004349. doi: 10.1371/journal.pntd.0004349. [PubMed: 26937644]. [PubMed Central: PMC4777430].
  • 3. David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22(6):491-502. doi: 10.1111/j.1529-8019.2009.01272.x. [PubMed: 19889134].
  • 4. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol. 2015;73(6):897-908. quiz 909-10. doi: 10.1016/j.jaad.2014.08.051. [PubMed: 26568335].
  • 5. Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle East: Incidence and epidemiology. PLoS Negl Trop Dis. 2014;8(10). e3208. doi: 10.1371/journal.pntd.0003208. [PubMed: 25275483]. [PubMed Central: PMC4183486].
  • 6. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5). e35671. doi: 10.1371/journal.pone.0035671. [PubMed: 22693548]. [PubMed Central: PMC3365071].
  • 7. Norouzinezhad F, Ghaffari F, Norouzinejad A, Kaveh F, Gouya MM. Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed. 2016;6(7):614-9. doi: 10.1016/j.apjtb.2016.05.005.
  • 8. Aflatoonian MR, Sharifi I, Fekri AR. [Evaluation of the cost-effectiveness of cutaneous leishmaniasis treatment after the earthquake in Bam]. J Kerman Univ Med Sci. 2009;16(4):365-73. Persian.
  • 9. Pazoki-Ghohe H, Haghparast-Kenari B, Fakhar M. [Current and novel laboratory diagnostic methods and identification of causative agents for cutaneous leishmaniasis]. J Mazandaran Univ Med Sci. 2016;25(132):350-66. Persian.
  • 10. Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: Current status and future directions. Mol Biol Int. 2011;2011:571242. doi: 10.4061/2011/571242. [PubMed: 22091408]. [PubMed Central: PMC3196053].
  • 11. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One. 2017;12(9). e0184777. doi: 10.1371/journal.pone.0184777. [PubMed: 28926630]. [PubMed Central: PMC5604971].
  • 12. Shirzadi M, Gouya MM. National guideline for Leishmaniasis surveillance in Iran. Tehran, Iran; 2012.
  • 13. Jo C. Cost-of-illness studies: Concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327-37. doi: 10.3350/cmh.2014.20.4.327. [PubMed: 25548737]. [PubMed Central: PMC4278062].
  • 14. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: A global systematic review. Pharmacoeconomics. 2015;33(8):811-31. doi: 10.1007/s40273-015-0268-9. [PubMed: 25787932]. [PubMed Central: PMC4519633].
  • 15. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med. 2015;130:42-50. doi: 10.1016/j.socscimed.2015.01.046. [PubMed: 25681713].
  • 16. Shirzadi MR, Esfahania SB, Mohebalia M, Ershadia MR, Gharachorlo F, Razavia MR, et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. East Mediterr Health J. 2015;21(10):736-42. [PubMed: 26750164].
  • 17. Saghafipour A, Vatandoost H, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Jooshin MK, Rassi Y, et al. Epidemiological study on cutaneous leishmaniasis in an endemic area, of Qom province, central Iran. J Arthropod Borne Dis. 2017;11(3):403-13. [PubMed: 29322057]. [PubMed Central: PMC5758636].
  • 18. Saghafipour A, Nejati J, Mozaffari E, Rezaei F, Gharlipour Z, Mirheydari M. The effectiveness of education based on BASNEF model on promoting preventive behavior of cutaneous leishmaniasis among students. Int J Pediatr. 2017;5(6):5125-36. doi: 10.22038/ijp.2017.22373.1875.
  • 19. Saghafipour A, Vatandoost H, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Rassi Y, Karami Jooshin M, et al. Control of zoonotic cutaneous leishmaniasis vector, Phlebotomus papatasi, using attractive toxic sugar baits (ATSB). PLoS One. 2017;12(4). e0173558. doi: 10.1371/journal.pone.0173558. [PubMed: 28426679]. [PubMed Central: PMC5398489].
  • 20. Saghafipour A, Mozaffari E, Rezaei F. The evaluation of intralesional glucantime and cryotherapy plus intralesional glucantime therapeutic efficacy on zoonotic cutaneous leishmaniasis: A randomized clinical trial. Int J Pediatr. 2017;5(12):6689-97. doi: 10.22038/ijp.2017.24545.2069.
  • 21. Rajabi A. The role of activity based costing (ABC) system in governmental hospital services in Iran. Iran Red Cres Med J. 2008;10(2):89-94.
  • 22. Aboagye AQ, Degboe AN, Obuobi AA. Estimating the cost of healthcare delivery in three hospitals in Southern Ghana. Ghana Med J. 2010;44(3):83-92. [PubMed: 21327011]. [PubMed Central: PMC2996840].
  • 23. Goeree R, Gafni A, Hannah M, Myhr T, Blackhouse G. Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference? Pharmacoeconomics. 1999;15(6):561-72. doi: 10.2165/00019053-199915060-00004. [PubMed: 10538329].
  • 24. Shepard DS, Hodgkin D, Yvann AE. Paydar A, translator. Analysis of hospital costs: A manual for managers. Tehran: Sogand Publication; 2001.
  • 25. Reithinger R, Coleman PG. Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: Cost-effectiveness of an operational program in a complex emergency setting. BMC Infect Dis. 2007;7:3. doi: 10.1186/1471-2334-7-3. [PubMed: 17263879]. [PubMed Central: PMC1790896].
  • 26. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg. 2001;65(5):466-70. [PubMed: 11716099].
  • 27. Guthmann JP, Arlt D, Garcia LM, Rosales M, de Jesus Sanchez J, Alvarez E, et al. Control of mucocutaneous leishmaniasis, a neglected disease: Results of a control programme in Satipo Province, Peru. Trop Med Int Health. 2005;10(9):856-62. doi: 10.1111/j.1365-3156.2005.01460.x. [PubMed: 16135192].
  • 28. Iraji F, Tavakoli R. Expense of treatment of cutaneous Leishmaniasis in Isfahan province in 1999. Iran J Dermatol. 1999;4(16):3-7.
  • 29. Ezenduka C, Ichoku H, Ochonma O. Estimating the costs of psychiatric hospital services at a public health facility in Nigeria. J Ment Health Policy Econ. 2012;15(3):139-48. [PubMed: 23001282].
  • 30. Mohammadi Y, Baghestani E, Bahrami MA, Entezarian Ardekani S, Ahmadi Tehrani GH. [Calculating the cost price of dialysis in Shahid Sadoughi Hospital using activity based costing: Yazd, 2011]. J Health Account. 2012;1(1):73-84. Persian.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments